Literature DB >> 26748387

Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

Mark D Hicar1, Xuemin Chen2, Spyros A Kalams3, Hakimuddin Sojar4, Gary Landucci5, Donald N Forthal5, Paul Spearman6, James E Crowe7.   

Abstract

Neutralizing antibodies (Abs) are thought to be a critical component of an appropriate HIV vaccine response. It has been proposed that Abs recognizing conformationally dependent quaternary epitopes on the HIV envelope (Env) trimer may be necessary to neutralize diverse HIV strains. A number of recently described broadly neutralizing monoclonal Abs (mAbs) recognize complex and quaternary epitopes. Generally, many such Abs exhibit extensive numbers of somatic mutations and unique structural characteristics. We sought to characterize the native antibody (Ab) response against circulating HIV focusing on such conformational responses, without a prior selection based on neutralization. Using a capture system based on VLPs incorporating cleaved envelope protein, we identified a selection of B cells that produce quaternary epitope targeting Abs (QtAbs). Similar to a number of broadly neutralizing Abs, the Ab genes encoding these QtAbs showed extensive numbers of somatic mutations. However, when expressed as recombinant molecules, these Abs failed to neutralize virus or mediate ADCVI activity. Molecular analysis showed unusually high numbers of mutations in the Ab heavy chain framework 3 region of the variable genes. The analysis suggests that large numbers of somatic mutations occur in Ab genes encoding HIV Abs in chronically infected individuals in a non-directed, stochastic, manner.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; B cells; HIV; Human; Monoclonal antibodies; Neutralization

Mesh:

Substances:

Year:  2015        PMID: 26748387      PMCID: PMC4762738          DOI: 10.1016/j.molimm.2015.12.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  45 in total

1.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.

Authors:  Chih-chin Huang; Miro Venturi; Shahzad Majeed; Michael J Moore; Sanjay Phogat; Mei-Yun Zhang; Dimiter S Dimitrov; Wayne A Hendrickson; James Robinson; Joseph Sodroski; Richard Wyatt; Hyeryun Choe; Michael Farzan; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

2.  A structure-based database of antibody variable domain diversity.

Authors:  Christopher J Bond; Christian Wiesmann; James C Marsters; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2005-05-06       Impact factor: 5.469

3.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Importance of conformation on the neutralizing antibody response to HIV-1 gp120.

Authors:  K S Steimer; N L Haigwood
Journal:  Biotechnol Ther       Date:  1991

5.  Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5.

Authors:  R Kunert; F Rüker; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-01       Impact factor: 2.205

6.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

Authors:  K S Steimer; C J Scandella; P V Skiles; N L Haigwood
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

10.  Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.

Authors:  John M Louis; Annie Aniana; Katheryn Lohith; Jane M Sayer; Julien Roche; Carole A Bewley; G Marius Clore
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

View more
  8 in total

1.  Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity.

Authors:  Hakimuddin Sojar; Sarah Baron; Jonathan T Sullivan; Meghan Garrett; Marlies M van Haaren; Jonathon Hoffman; Julie Overbaugh; Benjamin J Doranz; Mark D Hicar
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

2.  Clonal expansion and markers of directed mutation of IGHV4-34 B cells in plasmablasts during Kawasaki disease.

Authors:  Arthur J Chang; Sarah Baron; Jonathon Hoffman; Mark D Hicar
Journal:  Mol Immunol       Date:  2022-03-15       Impact factor: 4.174

3.  Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.

Authors:  Mark D Hicar; Xuemin Chen; Chidananda Sulli; Trevor Barnes; Jason Goodman; Hakimuddin Sojar; Bryan Briney; Jordan Willis; Valentine U Chukwuma; Spyros A Kalams; Benjamin J Doranz; Paul Spearman; James E Crowe
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

4.  Identification of HIV gp41-specific antibodies that mediate killing of infected cells.

Authors:  Katherine L Williams; Megan Stumpf; Nicole Elise Naiman; Shilei Ding; Meghan Garrett; Theodore Gobillot; Dani Vézina; Katharine Dusenbury; Nitya S Ramadoss; Ryan Basom; Peter S Kim; Andrés Finzi; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2019-02-19       Impact factor: 6.823

5.  Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.

Authors:  Michele Smith; Jonathon Hoffman; Hakimuddin Sojar; Ravikumar Aalinkeel; Chiu-Bin Hsiao; Mark Daniel Hicar
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

6.  Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity.

Authors:  Devin DeCotes; Sarah Baron; Jonathon Hoffman; Meghan Garrett; Hakimuddin Sojar; Mark D Hicar
Journal:  Arch Virol       Date:  2022-07-24       Impact factor: 2.685

7.  Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease.

Authors:  Ajit Monteiro; Arthur J Chang; R Ross Welliver; Sarah Baron; Mark D Hicar
Journal:  Virology       Date:  2022-09-02       Impact factor: 3.513

8.  B Cell Receptor Repertoire Analysis in Malaria-Naive and Malaria-Experienced Individuals Reveals Unique Characteristics of Atypical Memory B Cells.

Authors:  Ashley E Braddom; Sebastiaan Bol; S Jake Gonzales; Raphael A Reyes; Kenneth Musinguzi; Felistas Nankya; Isaac Ssewanyana; Bryan Greenhouse; Evelien M Bunnik
Journal:  mSphere       Date:  2021-09-15       Impact factor: 4.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.